> Details

Kröger, Nicolaus; Holler, Ernst; Kobbe, Guido; Bornhäuser, Martin; Schwerdtfeger, Rainer; Baurmann, Herrad; Nagler, Arnon; Bethge, Wolfgang; Stelljes, Matthias; Uharek, Lutz; Wandt, Hannes; Burchert, Andreas; Corradini, Paolo; Schubert, Jörg; Kaufmann, Martin; Dreger, Peter; Wulf, Gerald G.; Einsele, Hermann; Zabelina, Tatjana; Kvasnicka, Hans Michael; Thiele, Jürgen; Brand, Ronald; Zander, Axel R.; Niederwieser, Dietger;

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
  • Contributor: Kröger, Nicolaus; Holler, Ernst; Kobbe, Guido; Bornhäuser, Martin; Schwerdtfeger, Rainer; Baurmann, Herrad; Nagler, Arnon; Bethge, Wolfgang; Stelljes, Matthias; Uharek, Lutz; Wandt, Hannes; Burchert, Andreas; Corradini, Paolo; Schubert, Jörg; Kaufmann, Martin; Dreger, Peter; Wulf, Gerald G.; Einsele, Hermann; Zabelina, Tatjana; Kvasnicka, Hans Michael; Thiele, Jürgen; Brand, Ronald; Zander, Axel R.; Niederwieser, Dietger;
  • imprint: American Society of Hematology, 2009
  • Published in: Blood
  • Language: English
  • DOI: 10.1182/blood-2009-07-234880
  • ISSN: 0006-4971; 1528-0020
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:p>From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years (range, 32-68 years) were included in a prospective multicenter phase 2 trial to determine efficacy of a busulfan (10 mg/kg)/fludarabine (180 mg/m2)–based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related (n = 33) or unrelated donors (n = 70). All but 2 patients (2%) showed leukocyte and platelet engraftment after a median of 18 and 22 days, respectively. Acute graft-versus-host disease grade 2 to 4 occurred in 27% and chronic graft-versus-host disease in 43% of the patients. Cumulative incidence of nonrelapse mortality at 1 year was 16% (95% confidence interval, 9%-23%) and significantly lower for patients with a completely matched donor (12% vs 38%; P = .003). The cumulative incidence of relapse at 3 years was 22% (95% confidence interval, 13%-31%) and was influenced by Lille risk profile (low, 14%; intermediate, 22%; and high, 34%; P = .02). The estimated 5-year event-free and overall survival was 51% and 67%, respectively. In a multivariate analysis, age older than 55 years (hazard ratio = 2.70; P = .02) and human leukocyte antigen–mismatched donor (hazard ratio = 3.04; P = .006) remained significant factors for survival. The study was registered at www.clinicaltrials.gov as #NCT 00599547.</jats:p>
  • Access State: Open Access